Catalyst Pharma CEO on Reshoring Manufacturing and FDA Drug Approvals

Reshoring Manufacturing and Tariffs

• 🎯 Catalyst Pharma is well-positioned regarding tariffs, with 60% of its US sales manufactured domestically.
• 💡 The company has been prioritizing reshoring manufacturing to the US since before the Trump administration.
• 📈 Sales performance has been strong, with overall sales up 43.6% year-over-year and lead product sales up 25.3%.

Business Strategy and Sourcing

• 🧩 As a buy and build company, Catalyst Pharma focuses on acquiring products that have already cleared regulatory hurdles.
• 💰 The company can factor in existing tariffs when acquiring products manufactured in Europe, building this into their pricing calculus.
• ✅ This strategic approach positions them favorably to handle potential future tariffs on pharmaceuticals.

Focus on Rare Diseases and FDA

• 🔬 Catalyst Pharma's main drug is for Duchenne Muscular Dystrophy (DMD) and accounts for about two-thirds of their revenue.
• 🌟 The company supports FDA plans to speed up approvals for rare disease drugs, viewing it as a significant boost for the orphan drug community.